Please login to the form below

Not currently logged in
Email:
Password:

Voyager Therapeutics appoints chief financial officer

Jane Pritchett Henderson joins the gene therapy specialist

Voyager Jane HendersonCambridge, Massachusetts-based Voyager Therapeutics has appointed Jane Pritchett Henderson as senior vice president and chief financial officer.

Henderson brings nearly 30 years of life science and finance expertise to the firm, most recently as chief financial and business officer at Kolltan Pharmaceuticals.

Prior to this, she served as vice president of business development at ISTA Pharmaceuticals, chief financial officer and head of business development at Axerion Pharmaceuticals, and chief financial officer and chief business officer at Panacos Pharmaceuticals.

Henderson said: “Voyager has an excellent scientific foundation, world class researchers and clinicians, a stellar leadership team and board.

“This strong foundation combined with the company's recent positive interim phase Ib data from its lead program VY-AADC01 for advanced Parkinson's disease and the opportunity to join a company that has the potential to alter the course of treating devastating CNS diseases is highly attractive.

“I am thrilled to join the Voyager team and meaningfully contribute to the growth of the company by helping to bring the company's deep and rapidly progressing pipeline of innovative gene therapy programs to patients.”

11th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Precision medicine and the changing role of the healthcare professional
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of...
How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma...
eyeforpharma Barcelona 2017 highlights: Industry at the brink of transformation
Hear what Anthill's delegates reported back from the biggest eyeforpharma Barcelona yet....

Infographics